NeuroSense Therapeutics Ltd.

Company Overview

Business Model: NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for people living with neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and Parkinson’s Disease (PD). The company's strategy utilizes a combined therapeutic approach to target multiple disease-related pathways. Its lead therapeutic candidate, PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib, designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation.

Market Position: NeuroSense Therapeutics Ltd. operates in an intensely competitive biopharmaceutical industry characterized by rapid technological change and significant unmet medical needs in neurodegenerative diseases. The company aims to address the substantial burden of these diseases, with the ALS market alone estimated at over 80,000 patients in the United States and Europe, projected to grow by 24% by 2040. While current ALS treatments offer modest effects, NeuroSense Therapeutics Ltd. believes PrimeC's multifunctional mechanism of action and strong patent estate (including method of use, combination, and formulation patents) provide a competitive advantage. PrimeC has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ALS, and EMA's Small and Medium-Sized Enterprise (SME) status.

Recent Strategic Developments:

• PrimeC for ALS:
  • Completed PARADIGM, a Phase 2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study in 68 ALS patients.
  • December 2023: Met primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in top-line results.
  • May 2024: Announced statistically significant slowing of disease progression in high-risk ALS patients from PARADIGM data.
  • July 2024: Reported significant improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for PrimeC-treated subjects in 12-month PARADIGM analysis.
  • August 2024: Announced positive 12-month biomarker data from PARADIGM, showing a significant decrease in ferritin levels and a corresponding increase in transferrin levels.
  • October 2024: Completed full 18-month dosing in PARADIGM.
  • December 2024: Announced statistically significant positive results from the 18-month PARADIGM data analysis, indicating a disease-modifying effect.
  • February 2025: Announced additional 18-month PARADIGM findings, showing improvements in complication-free survival and Slow Vital Capacity (SVC).
  • Initiated a long-term toxicology study for ciprofloxacin (a component of PrimeC) as recommended by the FDA, with the in-life phase completed in September 2024.
  • December 2024: Concluded a Type C meeting with the FDA to discuss the design of a proposed Phase 3 clinical study and the plan for a 505(b)(2) marketing application.
  • Plans to submit a final protocol to the FDA in the first half of 2025, aiming to commence enrollment of a pivotal Phase 3 study (approximately 300 patients, 2:1 PrimeC to placebo, with a 12-month open label extension) in the second half of 2025.
  • October 2024: Plans to file for early commercialization approval for PrimeC under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy.
  • December 2024: Entered into a binding term sheet with a leading global pharmaceutical company for the development and commercialization of PrimeC in certain key territories. The term sheet includes a substantial upfront payment upon signing a definitive agreement, funding for the Phase 3 clinical trial, regulatory and net sales milestone payments, and a tiered royalty structure reaching double-digit percentages on annual net sales. NeuroSense Therapeutics Ltd. retains full rights to PrimeC in other key territories.
• AD Program:
  • Q4 2023: Initiated a randomized, prospective, double-blind, single-center, placebo-controlled Phase 2 study for PrimeC (an intermediate formulation of CogniC) in 20 patients with mild to moderate AD at the Rambam Medical Center in Israel. The study incorporates comprehensive biomarker analysis (cerebrospinal fluid and blood) and induced pluripotent stem cell (iPSC) generation.
  • This study builds on a proof-of-concept biomarker study that showed higher levels of known AD-implicated proteins (Aβ42, pTau, TDP-43) and altered Cathepsin D (CatD) and prostaglandin J2 (PgJ2) in AD patient samples.
• PD Program:
  • Preclinical pipeline includes StabiliC for PD.
  • Initial preclinical studies in an MPTP-induced PD model were not relevant.
  • Future plans include exploring StabiliC’s mode of action and assessing its ability to affect PD-related hallmarks using in-vitro patient-derived cells and an in-vivo rodent adeno-associated-virus alpha synuclein (AAV-SYN) model. StabiliC is planned as a combination of ciprofloxacin and celecoxib, and/or another molecule.
• Collaborations:
  • April 2024: Entered into a collaboration with Lonza to evaluate biological changes in people with neurodegenerative diseases, including ALS, leveraging Lonza’s extracellular vesicles expertise for biomarker development, optimization, and qualification for PrimeC.
  • March 2024: The Collaborative Evaluation Agreement with Biogen (entered May 2023) to evaluate PrimeC's impact on neurofilament levels was not continued.

Geographic Footprint:

• Corporate headquarters: Herzliya, Israel.
• Employees: 15 full and part-time employees, and several part-time consultants, primarily based in Herzliya, Israel, with others in Switzerland and the United States.
• Clinical trial sites: Israel (Tel Aviv Sourasky Medical Center, Rambam Medical Center), Italy, Canada, and the U.S. (Barrow Neurological Institute in Phoenix, Arizona).
• Manufacturing: Relies on third-party contract manufacturers located in India.
• Regulatory presence: Engages with the FDA (U.S.), EMA (Europe), and Health Canada.
• Patent protection: Holds patents in the U.S., European Patent Office, Japan, Canada, Australia, and Israel.

Cross-Border Operations:

• International Subsidiaries: NeuroSense Therapeutics Ltd. operates with wholly-owned subsidiaries, including a U.S. subsidiary.
• Joint Ventures: No explicit joint ventures are mentioned in the filing.
• Licensing Agreements: A binding term sheet has been signed with a leading global pharmaceutical company for an exclusive license to distribute, market, promote, sell, and develop PrimeC for ALS in certain key markets, with NeuroSense Therapeutics Ltd. retaining non-exclusive rights for research and manufacturing for PrimeC for ALS, and full rights in other key territories.
• Cross-Border Trade: The company relies on third-party contract manufacturers in India for raw materials, active ingredients, and finished products for its preclinical and clinical trials.
• Regulatory Compliance Across Jurisdictions: The company is subject to extensive and varying regulations by the FDA, EMA, Health Canada, and Israeli regulatory authorities, including requirements for clinical trials (GCP, GLP), manufacturing (cGMP), and marketing approvals.
• Currency Exposure: The U.S. dollar is the functional and reporting currency, but a significant portion of operating expenses are incurred in New Israeli Shekels (NIS), exposing the company to foreign exchange rate fluctuations.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: $5.698 million (2024), representing a decrease from $7.274 million in 2023.
• Capital Expenditures: $3 thousand (2024).
• Strategic Investments: The binding term sheet with a global pharmaceutical company includes funding for the Phase 3 clinical trial of PrimeC. NeuroSense Therapeutics Ltd. is also investing in the preclinical development of other product candidates and the Phase 2 AD program.

Currency Impact Analysis:

• Foreign exchange impact on revenue and earnings: The U.S. dollar is the functional and reporting currency. A significant portion of operating expenses are incurred in New Israeli Shekels (NIS). Fluctuations in the NIS/U.S. dollar exchange rate can affect U.S. dollar-denominated results. For the year ended December 31, 2024, exchange rate changes resulted in a net finance expense of $45 thousand. The U.S. dollar strengthened against the NIS by 0.55% in 2024.
• Hedging strategies and effectiveness: NeuroSense Therapeutics Ltd. does not currently hedge its foreign currency exchange risk but may consider formal currency hedging transactions in the future.
• Functional currency considerations: The U.S. dollar is the functional and reporting currency for NeuroSense Therapeutics Ltd. and its subsidiaries.

Business Segment Analysis

NeuroSense Therapeutics Ltd.'s Chief Executive Officer, who is the company’s chief operating decision maker, reviews financial information on an aggregate basis for evaluating financial performance and allocating resources. Accordingly, NeuroSense Therapeutics Ltd. has determined that it operates in a single reportable segment specializing in the development of treatments for patients suffering from debilitating neurodegenerative diseases.

International Operations & Geographic Analysis

Revenue by Geography: NeuroSense Therapeutics Ltd. has not recognized any revenue to date.

International Business Structure:

• Subsidiaries: NeuroSense Therapeutics Ltd. operates with wholly-owned subsidiaries, including a U.S. subsidiary.
• Joint Ventures: No explicit joint ventures are mentioned in the filing.
• Licensing Agreements: NeuroSense Therapeutics Ltd. has entered into a binding term sheet with a leading global pharmaceutical company for an exclusive license to distribute, market, promote, sell, and develop PrimeC for ALS in certain key markets. NeuroSense Therapeutics Ltd. retains non-exclusive rights for research and manufacturing for PrimeC for ALS, and full rights in other key territories.
• Cross-Border Trade:
  • Export Markets: Not applicable, as NeuroSense Therapeutics Ltd. has no commercial products yet.
  • Import Dependencies: NeuroSense Therapeutics Ltd. relies on third-party contract manufacturers and suppliers for all required raw materials, active ingredients, and finished products for its preclinical research and clinical trials. Manufacturing is conducted in India.
  • Transfer Pricing: Inter-company transactions and policies are not explicitly detailed, but transfer pricing risks are acknowledged in the risk assessment framework.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: NeuroSense Therapeutics Ltd. has not engaged in any share repurchase programs.
• Dividend Payments: NeuroSense Therapeutics Ltd. has never declared or paid cash dividends on its share capital and does not anticipate paying any cash dividends in the foreseeable future. The company intends to retain all available funds and any future earnings to fund the development and growth of its business.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No future capital return commitments are disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $3.378 million
• Total Debt: NeuroSense Therapeutics Ltd. does not report a single "Total Debt" figure. Its liabilities primarily consist of current obligations.
  • Current Liabilities: $1.992 million (comprising $1.160 million in trade payables and $0.832 million in other current liabilities, which includes a short-term lease liability of $73 thousand).
  • Non-Current Liabilities: $0 (the liability in respect of warrants was reclassified to equity in 2024).
• Net Cash Position: $1.386 million (Cash and Cash Equivalents less Total Liabilities).
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The current portion of the lease liability is $73 thousand as of December 31, 2024, with no non-current lease liability.

Cash Flow Generation (Year Ended December 31, 2024):

• Operating Cash Flow: $(10.135) million (net cash used in operating activities).
• Free Cash Flow: $(10.138) million (Operating Cash Flow less $3 thousand in Capital Expenditures).
• Cash Conversion Metrics: Not explicitly disclosed.

Currency Management:

• Cash holdings by major currencies: As of December 31, 2024, NeuroSense Therapeutics Ltd. held $3.057 million in New Israeli Shekels (NIS) and $0.321 million in U.S. dollars.
• Natural hedging through operational diversification: Not explicitly detailed, but the company's operational expenses in NIS and expected future revenues in U.S. dollars may provide some natural hedging.
• Financial hedging instruments and strategies: NeuroSense Therapeutics Ltd. does not currently hedge its foreign currency exchange risk but may enter into formal currency hedging transactions in the future.

Operational Excellence

Production & Service Model: NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of treatments for neurodegenerative diseases, employing a combined therapeutic approach. The company does not own or operate its own manufacturing facilities. Instead, it relies entirely on third-party contract manufacturers for all required raw materials, active ingredients, and finished products necessary for its preclinical research and clinical trials. The company plans to negotiate commercial supply agreements and back-up supply agreements with other third-party manufacturers to support commercial-scale production if its product candidates receive regulatory approval. All manufacturing processes must comply with current Good Manufacturing Practices (cGMP) and current Good Laboratory Practices (cGLP) as mandated by regulatory authorities.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers: Third-party contract manufacturers are utilized for raw materials, active ingredients, and finished products for preclinical and clinical trials. Manufacturing of drug products is conducted in India.
• Clinical Research Organizations (CROs): NeuroSense Therapeutics Ltd. relies on CROs, medical institutions, clinical investigators, and contract laboratories to conduct its clinical trials.
• Technology Partners:
  • Lonza: Collaboration to evaluate biological changes in neurodegenerative diseases, including ALS, providing access to Lonza’s extracellular vesicles expertise for biomarker development, optimization, and qualification for PrimeC.

Facility Network:

• Manufacturing: NeuroSense Therapeutics Ltd. outsources all manufacturing to third-party contract manufacturers, with current production located in India.
• Research & Development: R&D activities are managed from the corporate headquarters in Herzliya, Israel. Clinical trials are conducted at various sites including Tel Aviv Sourasky Medical Center (Israel), Rambam Medical Center (Israel), Barrow Neurological Institute (Phoenix, Arizona, U.S.), and sites in Italy and Canada.
• Distribution: A commercial distribution network has not yet been established, as the company has no approved products for sale.

Operational Metrics: Specific quantitative operational metrics such as capacity utilization or efficiency measures are not explicitly disclosed in the filing. However, compliance with cGMP and cGLP requirements by contract manufacturers is a key operational standard.

Market Access & Customer Relationships

Go-to-Market Strategy: NeuroSense Therapeutics Ltd. has not yet established a commercial organization for the marketing, sale, and distribution of its product candidates. The company plans to either build internal marketing, sales, and distribution capabilities or contract with third parties to obtain these services.

• Distribution Channels: Future commercialization efforts will involve direct sales or partnerships with channel partners.
• Channel Partners: A binding term sheet has been signed with a leading global pharmaceutical company for an exclusive license to distribute, market, promote, sell, and develop PrimeC for ALS in certain key markets.
• Digital Platforms: While the company uses its website for information distribution, specific digital platforms for sales or e-commerce initiatives are not detailed.

Customer Portfolio:

• Enterprise Customers: Not applicable, as NeuroSense Therapeutics Ltd. currently has no commercial products.
• Strategic Partnerships: The company has a binding term sheet with a leading global pharmaceutical company for the commercialization of PrimeC in certain key territories.
• Customer Concentration: Not applicable, as there are no commercial products or customers yet.

Regional Market Penetration:

• Growth Markets: The target market for ALS in the United States and Europe is estimated to grow by 24% by 2040, indicating significant potential for future market penetration upon product approval. NeuroSense Therapeutics Ltd. is pursuing regulatory approvals and potential early commercialization in multiple regions, including the U.S., Europe, and Canada.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is intensely competitive and characterized by rapid and significant technological change. Neurodegenerative diseases, including ALS, AD, and PD, represent substantial unmet medical needs with limited effective therapeutic options. The development of new drugs is a lengthy, expensive, and uncertain process, subject to extensive and rigorous regulation that varies by country. The economic burden of these diseases is significant, with ALS alone costing an estimated $180,000 per patient annually and imposing over $1 billion on the U.S. healthcare system.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• ALS: NeuroSense Therapeutics Ltd. faces competition from numerous large and specialty pharmaceutical and biotechnology companies, as well as academic institutions. Key competitors include Biogen, Amylyx Pharmaceuticals, Novartis, MT-Pharma, Sanofi, AB Science, Prilenia Therapeutics, Brainstorm Cell Therapeutics, Clene, Corcept Therapeutics, Cytokinetics, Denali Therapeutics, Seelos, Eledon, QurAlis, and Apellis Pharmaceuticals, all of whom are developing potentially disease-modifying therapeutics in various stages of clinical trials. Existing approved drugs like Rilutek and Radicava offer modest effects, and Qalsody targets a small subset of the ALS population (SOD1 mutation, ~2%).
• Alzheimer’s Disease: Competitors developing potentially disease-modifying therapeutics include Biogen, Eli Lilly, Eisai, Roche (including Genentech Inc.), and Alector.
• Parkinson’s Disease: Key competitors include Prothena, Roche (including Genentech Inc.), Prevail/Eli Lilly, AstraZeneca, and Takeda.

Regional Competitive Dynamics: The competitive landscape varies by major geographic markets, with numerous companies pursuing treatments for neurodegenerative diseases globally. NeuroSense Therapeutics Ltd.'s strategy includes seeking early commercialization approval in Canada and a global partnership for PrimeC, indicating a multi-regional approach to navigate these dynamics.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics:

• Economic and Market Conditions: NeuroSense Therapeutics Ltd.'s business is susceptible to unfavorable global economic and market conditions, including volatility, inflation, interest rate increases, and liquidity shortages. Geopolitical events such as the war between Russia and Ukraine, the current war between Israel and Hamas, terrorism, and other regional conflicts can adversely affect business conditions, sales cycles, technology adoption, and the ability to secure financing.
• Technology Disruption: The biopharmaceutical industry is characterized by rapid technological advancements. Competitors may develop new drugs or technologies that are more effective or less costly than NeuroSense Therapeutics Ltd.'s product candidates, or scientific breakthroughs could render its products obsolete.
• Customer Concentration: Not applicable, as NeuroSense Therapeutics Ltd. has no commercial products or customers to date.

Operational & Execution Risks

Global Supply Chain Vulnerabilities:

• Supplier Dependency: NeuroSense Therapeutics Ltd. relies on a limited number of third-party contract manufacturers and suppliers in India for raw materials, active ingredients, and finished products for its preclinical and clinical trials. This creates a risk of supply disruptions, inability to obtain sufficient quantities at acceptable costs, or non-compliance with quality standards (cGMP, cGLP).
• Regional Disruptions: Manufacturing difficulties, including issues with production costs, yields, quality control, contamination, labor disputes, or unstable political environments, could delay or halt clinical trials and commercialization efforts.
• Trade Restrictions: While not explicitly detailed, the company is exposed to general risks associated with export controls, tariffs, and trade war impacts that could affect its global supply chain.
• Clinical Trial Risks: Clinical drug development is lengthy, expensive, and uncertain. Delays or failures can arise from patient enrollment challenges, regulatory approval processes, performance of Contract Research Organizations (CROs), unforeseen safety or efficacy issues, and funding limitations. NeuroSense Therapeutics Ltd. has limited experience in conducting clinical trials.
• Manufacturing Risks: The complex nature of pharmaceutical manufacturing, including scaling up and validating production, and maintaining contamination controls, poses risks. Non-compliance with cGMP or cGLP by third-party manufacturers could lead to sanctions, product recalls, or withdrawal of approvals.
• Growth Management: Ineffective management of the expansion of development, quality, sales, managerial, operational, finance, and marketing resources could disrupt business operations.
• Key Personnel: The company's success depends on attracting and retaining highly qualified senior management and key scientific personnel. Loss of these individuals could delay product development and commercialization.
• IT Systems/Cybersecurity: Internal computer systems and those of contractors are vulnerable to cybersecurity threats, including malware and unauthorized access. Such incidents could disrupt drug development programs, lead to data loss or damage, or inappropriate disclosure of confidential information.

Financial & Regulatory Risks

Currency & Financial Risks:

• Foreign Exchange: NeuroSense Therapeutics Ltd. is exposed to foreign exchange risk due to significant operating expenses in New Israeli Shekels (NIS) and expected future revenues in U.S. dollars. The company does not currently hedge this risk.
• Interest Rate Risk: General economic conditions and interest rate fluctuations can impact the cost and availability of future financing.
• Credit & Liquidity: NeuroSense Therapeutics Ltd. has a history of recurring losses and negative cash flows, with an accumulated deficit of $36.66 million as of December 31, 2024. Its cash and cash equivalents of $3.378 million as of the same date are not sufficient to fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern. Substantial additional financing is required, and failure to obtain it could delay or terminate product development and commercialization.
• PFIC Status: NeuroSense Therapeutics Ltd. expects to be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences for U.S. investors.
• Shareholder Dilution: Future capital raises through equity or convertible debt securities may dilute existing shareholder ownership.
• Going Concern: The company's financial statements include a going concern reference, highlighting the need for additional financing to sustain operations.

Regulatory & Compliance Risks:

• Multi-Jurisdictional Compliance: The company operates in a highly regulated environment, subject to extensive and differing regulations by the FDA, EMA, Health Canada, and Israeli authorities. Non-compliance can lead to significant penalties.
• Approval Pathway: There is a risk that the FDA may not conclude that PrimeC satisfies the requirements for the 505(b)(2) regulatory pathway, which could significantly lengthen and increase the cost of the approval process.
• Post-Approval Requirements: Even if product candidates receive regulatory approval, they will be subject to ongoing regulatory obligations, including post-marketing studies, Risk Evaluation and Mitigation Strategies (REMS), labeling restrictions, and potential market withdrawal if problems arise.
• Off-Label Promotion: Improper promotion of products for unapproved uses could lead to significant sanctions, product liability claims, and reputational harm.
• Healthcare Reform: Legislative and regulatory changes in healthcare (e.g., ACA, Inflation Reduction Act) in the U.S. and abroad could limit reimbursement, increase costs, or restrict sales and promotional activities for approved products.
• Orphan Drug Exclusivity: Orphan Drug Designation for PrimeC may not guarantee market exclusivity against different drugs for the same condition or if a competitor demonstrates clinical superiority.
• Fraud and Abuse Laws: Relationships with healthcare professionals and other third parties are subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), transparency laws, and government price reporting. Non-compliance could result in severe penalties.
• Intellectual Property: Risks include inadequate patent protection, challenges to patent validity or enforceability, inability to protect trade secrets, changes in patent law (e.g., AIA), and third-party claims of infringement.
• Israeli Law: Provisions of Israeli corporate law and the company's articles of association may delay or prevent mergers or acquisitions. Enforcing U.S. court judgments in Israel can be difficult, and shareholder rights are governed by Israeli law, which differs from U.S. law.

Geopolitical & External Risks

Country-Specific Risks:

• Political Risk (Israel): NeuroSense Therapeutics Ltd.'s operations in Israel are directly affected by the economic, political, geopolitical, and military conditions in the region, including the ongoing war between Israel and Hamas, clashes with Hezbollah, and attacks from Iran. These conflicts could disrupt operations, lead to employee absences due to reserve military service, make it difficult to raise capital, and adversely affect the market price of the company's shares. Commercial insurance typically does not cover war-related losses.
• Economic Risk: Economic instability in Israel, including currency devaluation (NIS/USD), could negatively impact the company's financial condition.
• Regulatory Changes: Changes in local laws and regulations in Israel could affect the company's operations.

Innovation & Technology Leadership

Research & Development Focus: NeuroSense Therapeutics Ltd. is dedicated to discovering and developing treatments for neurodegenerative diseases through a combined therapeutic approach.

• Global R&D Network: R&D activities are managed from the corporate headquarters in Herzliya, Israel. Clinical trials are conducted across multiple international sites, including Tel Aviv Sourasky Medical Center and Rambam Medical Center in Israel, Barrow Neurological Institute in Phoenix, Arizona, U.S., and clinical sites in Italy and Canada.
• Innovation Pipeline:
  • PrimeC (ALS): The lead product candidate is a novel extended-release oral formulation combining ciprofloxacin and celecoxib. Its R&D focus is on modulating microRNA synthesis, iron accumulation, and neuroinflammation. A pivotal Phase 3 study is planned.
  • CogniC (AD): An intermediate formulation of PrimeC, currently in a Phase 2 study, focusing on addressing AD pathology by targeting proteins like Aβ42, pTau, TDP-43, CatD, and PgJ2.
  • StabiliC (PD): In preclinical development, this candidate is planned as a combination of ciprofloxacin and celecoxib, and/or another molecule. R&D efforts are focused on exploring its mode of action and assessing its ability to reduce AAV-SYN aggregation and improve morphological and functional markers in PD models.
• Technology Development: The company utilizes advanced techniques such as neuron-derived exosomes (NDEs) for biomarker analysis and induced pluripotent stem cells (iPSCs) to study disease mechanisms and drug response at the cellular level.

Intellectual Property Portfolio:

• Patent Strategy: NeuroSense Therapeutics Ltd. maintains a strong patent estate, including patents on method of use, combination, and formulation.
  • U.S. Patent 10,980,780, covering methods for the treatment of ALS using ciprofloxacin and celecoxib, expires in 2038. Equivalent patents have been issued in the European Patent Office, Japan, Canada, Australia, and Israel.
  • U.S. patent application 16/623,467, related to methods of treatment of neurodegenerative disease using combinations of ciprofloxacin and celecoxib, is pending and expected to expire on June 20, 2038.
  • US Patent 12,097,185, pertaining to pharmaceutical compositions of ciprofloxacin and celecoxib formulations, expires in December 2042, with equivalent applications pending worldwide.
• Licensing Programs: A binding term sheet has been established with a leading global pharmaceutical company for an exclusive license to distribute, market, promote, sell, and develop PrimeC for ALS in certain key territories.
• IP Litigation: The company acknowledges the risk of third-party infringement claims and challenges to its patent validity or enforceability.

Technology Partnerships:

• Strategic Alliances: NeuroSense Therapeutics Ltd. has a collaboration with Lonza, leveraging their expertise in extracellular vesicles for biomarker development, optimization, and qualification for PrimeC in neurodegenerative diseases.
• Research Collaborations: The company has collaborated with Mass General Hospital (MGH) in Boston for neuron-derived exosomes biomarker analysis in ALS.

Leadership & Governance

Executive Leadership Team

International Management Structure: Most of NeuroSense Therapeutics Ltd.'s officers and employees are residents of Israel, with additional employees and consultants located in Switzerland and the United States. The Chief Operating Officer, Hagit Binder, is appointed as the General Manager in Israel, commencing May 1, 2025, indicating a regional leadership role.

Board Composition: The Board of Directors includes Mark Leuchtenberger as Chair, Cary Claiborne and Christine Pellizzari as External Directors (under Israeli Companies Law), and Roy Golan and Dr. Revital Mandil-Levin as Directors. Mark Leuchtenberger, Cary Claiborne, Christine Pellizzari, and Roy Golan are independent directors under Nasdaq rules. The board is structured with staggered three-year terms for non-external directors. The Audit Committee consists of Cary Claiborne (Chair), Christine Pellizzari, and Roy Golan. The Compensation Committee consists of Christine Pellizzari (Chair), Cary Claiborne, and Dr. Revital Mandil-Levin. All external directors serve on these committees, and an external director chairs each, in compliance with Israeli Companies Law and Nasdaq corporate governance rules (with certain home country practice exemptions).

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: NeuroSense Therapeutics Ltd. operates under extensive and rigorous regulatory frameworks in multiple jurisdictions. Primary Regulatory Environments:

• United States (FDA): Product candidates are subject to the Federal Food, Drug and Cosmetic Act (FDCA). This includes requirements for preclinical studies (Good Laboratory Practices - GLP), submission of Investigational New Drug (IND) applications, human clinical trials (Good Clinical Practice - GCP), New Drug Application (NDA) submissions (specifically pursuing the 505(b)(2) pathway for PrimeC), manufacturing facility inspections (current Good Manufacturing Practices - cGMP), and post-approval monitoring (e.g., Risk Evaluation and Mitigation Strategies - REMS, Phase 4 clinical trials).
• European Union (EMA): Marketing authorizations can be pursued through centralized, national, decentralized, or mutual recognition procedures, each with distinct requirements.
• Canada (Health Canada): NeuroSense Therapeutics Ltd. plans to file for early commercialization approval for PrimeC under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy.
• Israel (MOH): Clinical studies require specific authorization from institutional ethics committees and general managers, and often from the Israeli Ministry of Health (MOH). Drug registration is governed by the Pharmacists Regulations and MOH guidelines, with initial approvals for up to five years and renewals for up to ten years. The first batch of a pharmaceutical marketed in Israel must also receive MOH approval.

Cross-Border Compliance:

• Export Controls: Not explicitly detailed, but general risks related to trade restrictions are acknowledged.
• Sanctions Compliance: Not explicitly detailed, but general risks related to trade restrictions are acknowledged.
• Anti-Corruption: NeuroSense Therapeutics Ltd. is subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws. The company has adopted a code of business conduct and ethics to promote compliance.
• Trade Regulations: Compliance with various federal and state healthcare fraud and abuse laws in the U.S., including the Anti-Kickback Statute, False Claims Act, Health Insurance Portability and Accountability Act (HIPAA), transparency laws, and government price reporting requirements.

International Tax Strategy:

• Transfer Pricing: Inter-company transactions and policies are not explicitly detailed, but transfer pricing risks are acknowledged in the risk assessment framework.
• Tax Treaties: The U.S.-Israel Tax Treaty is relevant for capital gains and dividends, potentially offering reduced tax rates or exemptions for non-Israeli resident securityholders under certain conditions.
• BEPS Compliance: Not explicitly detailed in the filing.
• Israeli Corporate Tax: Israeli companies are generally subject to a corporate tax rate of 23%. NeuroSense Therapeutics Ltd. may qualify for reduced corporate tax rates (e.g., 12% or 7.5%) on income derived from a "Preferred Technological Enterprise" under the Law for the Encouragement of Capital Investments.

Environmental & Social Impact

Global Sustainability Strategy: NeuroSense Therapeutics Ltd. does not explicitly detail a global sustainability strategy, environmental commitments, carbon neutrality targets, or renewable energy adoption in the provided filing.

Social Impact by Region:

• Community Investment: NeuroSense Therapeutics Ltd. maintains steadfast and extensive communication and collaboration with patient advocacy groups and associations, underscoring the importance of patient perspectives in advancing therapeutic strategies.
• Labor Standards: The company's employees are engaged under employment contracts that include provisions for social benefits as mandated by Israeli law. The company considers its relationship with employees to be positive.

Currency Management & Financial Strategy

Multi-Currency Operations: NeuroSense Therapeutics Ltd.'s functional and reporting currency is the U.S. dollar. However, a significant portion of its operating expenses are incurred in New Israeli Shekels (NIS). Currency Exposure (as of December 31, 2024):

Hedging Strategies:

• Transaction Hedging: NeuroSense Therapeutics Ltd. does not currently hedge its foreign currency exchange risk.
• Translation Hedging: Not explicitly detailed in the filing.
• Economic Hedging: Not explicitly detailed in the filing. NeuroSense Therapeutics Ltd. may enter into formal currency hedging transactions in the future to mitigate financial exposure from fluctuations in exchange rates.